Voriconazole is commonly recommended as a first‐line therapy for invasive aspergillosis infections. The elderly patients are susceptible to infectious diseases owing to their decreased physical function and immune system. Our study aims to establish a population‐based pharmacokinetic model for receiving intravenous voriconazole of elderly patients, and to optimize dosing protocols through a simulated approach. An accurate fit to the concentration‐time profile of voriconazole was achieved by employing a one‐compartment model featuring first‐order elimination. The typical clearance rate of voriconazole was found to be 3.22 L/h, with a typical volume of distribution of 194 L. The covariate analysis revealed that albumin (ALB), gamma glutamyl transpeptidase, and direct bilirubin had significant impacts on voriconazole clearance. Additionally, the body weight was found to be associated with the volume. Individualized dosing regimens were recommended for different ALB levels based on population PK model prediction. The proposed dosing regimens could provide a rationale for dosage individualization, improve the clinical outcomes and minimize drug‐related toxicities.This article is protected by copyright. All rights reserved